Physician profile
Rahul Dixit
NPI 1508073057
$94,995.61
in general payments reported to CMS, 2019-2025
40 companies · $6,852 in 2025
The $6,852 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $24K · 2021: $17K · 2022: $11K · 2023: $8,526 · 2024: $3,191 · 2025: $6,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $5,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,750.00 |
| Food and Beverage | $5,819.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $58,154.17 | 2019-2021 | |
| Abbvie INC. | $28,994.12 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,980.15 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $600.86 | 2019-2025 | Stelara, Tremfya, Simponi |
| Allergan, INC. | $542.33 | 2019 | |
| Pfizer INC. | $466.52 | 2019-2025 | |
| Celgene Corporation | $431.34 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $400.49 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $391.49 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $350.89 | 2019-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $334.48 | 2019-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $328.82 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $279.79 | 2019-2024 | Dificid |
| Intuitive Surgical, INC. | $193.03 | 2021 | |
| Aimmune Therapeutics, INC. | $138.17 | 2024-2025 | Vowst |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.